Gustavo E Velásquez1, Mercedes C Becerra2, Irina Y Gelmanova3, Alexander D Pasechnikov3, Askar Yedilbayev3, Sonya S Shin4, Yevgeny G Andreev5, Galina Yanova6, Sidney S Atwood7, Carole D Mitnick2, Molly F Franke8, Michael L Rich2, Salmaan Keshavjee2. 1. Division of Infectious Diseases, Brigham and Women's Hospital. 2. Department of Global Health and Social Medicine, Harvard Medical School Partners In Health, Boston, Massachusetts Partners In Health, Moscow, Russian Federation Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts. 3. Partners In Health, Boston, Massachusetts Partners In Health, Moscow, Russian Federation. 4. Partners In Health, Boston, Massachusetts Partners In Health, Moscow, Russian Federation Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts. 5. Tomsk Penitentiary Services, Ministry of Justice. 6. Tomsk Oblast Tuberculosis Hospital, Russian Federation. 7. Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts. 8. Department of Global Health and Social Medicine, Harvard Medical School Partners In Health, Boston, Massachusetts Partners In Health, Moscow, Russian Federation.
Abstract
BACKGROUND: Evidence is sparse regarding the optimal construction of regimens to treat multidrug-resistant (MDR) tuberculosis disease due to strains of Mycobacterium tuberculosis resistant to at least both isoniazid and rifampin. Given the low potency of many second-line antituberculous drugs, we hypothesized that an aggressive regimen of at least 5 likely effective drugs during the intensive phase, including a fluoroquinolone and a parenteral agent, would be associated with a reduced risk of death or treatment failure. METHODS: We conducted a retrospective cohort study of patients initiating MDR tuberculosis treatment between 2000 and 2004 in Tomsk, Russian Federation. We used a multivariate Cox proportional hazards model to assess whether monthly exposure to an aggressive regimen was associated with the risk of death or treatment failure. RESULTS: Six hundred fourteen individuals with confirmed MDR tuberculosis were eligible for analysis. On multivariable analysis that adjusted for extensively drug-resistant (XDR) tuberculosis-MDR tuberculosis isolates resistant to fluoroquinolones and parenteral agents-we found that monthly exposure to an aggressive regimen was significantly associated with a lower risk of death or treatment failure (hazard ratio, 0.52 [95% confidence interval, .29-.94]; P = .030). CONCLUSIONS: Receipt of an aggressive treatment regimen was a robust predictor of decreased risk of death or failure during MDR tuberculosis treatment. These findings further support the use of this regimen definition as the benchmark for the standard of care of MDR tuberculosis patients and should be used as the basis for evaluating novel therapies.
BACKGROUND: Evidence is sparse regarding the optimal construction of regimens to treat multidrug-resistant (MDR) tuberculosis disease due to strains of Mycobacterium tuberculosis resistant to at least both isoniazid and rifampin. Given the low potency of many second-line antituberculous drugs, we hypothesized that an aggressive regimen of at least 5 likely effective drugs during the intensive phase, including a fluoroquinolone and a parenteral agent, would be associated with a reduced risk of death or treatment failure. METHODS: We conducted a retrospective cohort study of patients initiating MDR tuberculosis treatment between 2000 and 2004 in Tomsk, Russian Federation. We used a multivariate Cox proportional hazards model to assess whether monthly exposure to an aggressive regimen was associated with the risk of death or treatment failure. RESULTS: Six hundred fourteen individuals with confirmed MDR tuberculosis were eligible for analysis. On multivariable analysis that adjusted for extensively drug-resistant (XDR) tuberculosis-MDR tuberculosis isolates resistant to fluoroquinolones and parenteral agents-we found that monthly exposure to an aggressive regimen was significantly associated with a lower risk of death or treatment failure (hazard ratio, 0.52 [95% confidence interval, .29-.94]; P = .030). CONCLUSIONS: Receipt of an aggressive treatment regimen was a robust predictor of decreased risk of death or failure during MDR tuberculosis treatment. These findings further support the use of this regimen definition as the benchmark for the standard of care of MDR tuberculosispatients and should be used as the basis for evaluating novel therapies.
Authors: M E Kimerling; H Kluge; N Vezhnina; T Iacovazzi; T Demeulenaere; F Portaels; F Matthys Journal: Int J Tuberc Lung Dis Date: 1999-05 Impact factor: 2.373
Authors: Joia S Mukherjee; Michael L Rich; Adrienne R Socci; J Keith Joseph; Felix Alcántara Virú; Sonya S Shin; Jennifer J Furin; Mercedes C Becerra; Donna J Barry; Jim Yong Kim; Jaime Bayona; Paul Farmer; Mary C Smith Fawzi; Kwonjune J Seung Journal: Lancet Date: 2004-02-07 Impact factor: 79.321
Authors: A Theisen; C Reichel; S Rüsch-Gerdes; W H Haas; J K Rockstroh; U Spengler; T Sauerbruch Journal: Lancet Date: 1995-06-10 Impact factor: 79.321
Authors: Carole Mitnick; Jaime Bayona; Eda Palacios; Sonya Shin; Jennifer Furin; Felix Alcántara; Epifanio Sánchez; Madeleny Sarria; Mercedes Becerra; Mary C Smith Fawzi; Saidi Kapiga; Donna Neuberg; James H Maguire; Jim Yong Kim; Paul Farmer Journal: N Engl J Med Date: 2003-01-09 Impact factor: 91.245
Authors: Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies Journal: Eur Respir J Date: 2012-10-25 Impact factor: 16.671
Authors: Molly F Franke; Mercedes C Becerra; Dylan B Tierney; Michael L Rich; Cesar Bonilla; Jaime Bayona; Megan M McLaughlin; Carole D Mitnick Journal: Ann Am Thorac Soc Date: 2015-05
Authors: R I Calderón; G E Velásquez; M C Becerra; Z Zhang; C C Contreras; R M Yataco; J T Galea; L W Lecca; A L Kritski; M B Murray; C D Mitnick Journal: Int J Tuberc Lung Dis Date: 2017-08-01 Impact factor: 2.373
Authors: A M W Efsen; A Schultze; R F Miller; A Panteleev; A Skrahin; D N Podlekareva; J M Miro; E Girardi; H Furrer; M H Losso; J Toibaro; J A Caylà; A Mocroft; J D Lundgren; F A Post; O Kirk Journal: J Infect Date: 2017-10-20 Impact factor: 6.072
Authors: S K Heysell; O B Ogarkov; S Zhdanova; E Zorkaltseva; S Shugaeva; J Gratz; S Vitko; E D Savilov; M E Koshcheyev; E R Houpt Journal: Int J Tuberc Lung Dis Date: 2016-02 Impact factor: 2.373
Authors: J Peter Cegielski; Ekaterina Kurbatova; Martie van der Walt; Jeannette Brand; Julia Ershova; Thelma Tupasi; Janice Campos Caoili; Tracy Dalton; Carmen Contreras; Martin Yagui; Jaime Bayona; Charlotte Kvasnovsky; Vaira Leimane; Liga Kuksa; Michael P Chen; Laura E Via; Soo Hee Hwang; Melanie Wolfgang; Grigory V Volchenkov; Tatiana Somova; Sarah E Smith; Somsak Akksilp; Wanpen Wattanaamornkiet; Hee Jin Kim; Chang-Ki Kim; Boris Y Kazennyy; Tatiana Khorosheva; Kai Kliiman; Piret Viiklepp; Ruwen Jou; Angela Song-En Huang; Irina A Vasilyeva; Olga V Demikhova; Joey Lancaster; Ronel Odendaal; Lois Diem; Therese C Perez; Tarcela Gler; Kathrine Tan; Cesar Bonilla; Oswaldo Jave; Luis Asencios; Gloria Yale; Carmen Suarez; Allison Taylor Walker; Inga Norvaisha; Girts Skenders; Ingrida Sture; Vija Riekstina; Andra Cirule; Erika Sigman; Sang-Nae Cho; Ying Cai; Seokyong Eum; Jongseok Lee; Seungkyu Park; Doosoo Jeon; Isdore C Shamputa; Beverly Metchock; Tatiana Kuznetsova; Rattanawadee Akksilp; Wanlaya Sitti; Jirapan Inyapong; Elena V Kiryanova; Irina Degtyareva; Evgenia S Nemtsova; Klavdia Levina; Manfred Danilovits; Tiina Kummik; Yung-Chao Lei; Wei-Lun Huang; Vladislav V Erokhin; Larisa N Chernousova; Sofia N Andreevskaya; Elena E Larionova; Tatyana G Smirnova Journal: Clin Infect Dis Date: 2015-10-27 Impact factor: 9.079
Authors: Noton K Dutta; Natalie Bruiners; Matthew D Zimmerman; Shumin Tan; Véronique Dartois; Maria L Gennaro; Petros C Karakousis Journal: J Infect Dis Date: 2020-03-16 Impact factor: 5.226
Authors: Scott K Heysell; Shahriar Ahmed; Sara Sabrina Ferdous; Md Siddiqur Rahman Khan; S M Mazidur Rahman; Jean Gratz; Md Toufiq Rahman; Asif Mujtaba Mahmud; Eric R Houpt; Sayera Banu Journal: PLoS One Date: 2015-02-24 Impact factor: 3.240